Gland Pharma Ltd
Gland Pharma Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin. FY'26 overall growth guidance: mid-teens percentage (15%-17%), driven by US business growth, new launches, tech transfer projects, dry powder contracts, and biologics segment (~Rs 100 crores revenue expected in FY'26).
From Gland Pharma Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin.
- Consolidated growth guidance for next year (FY'26): mid-teen percentage growth (~15%).
- Key US growth drivers FY'26: improvement in Cenexi numbers, new product launches, tech transfer projects, dry powder contracts (~Rs 60-70 crores), biologics (~Rs 100 crores).
- US volume growth notable in top products (24% volume increase in top 10 products).
- GLP cartridge fill-and-finish market expected to expand significantly; capacity to increase to 140 million cartridges next year from 40 million.
- ROW business expected to double over next 3-5 years via product registrations and cost efficiencies.
- Cenexi to break even by December quarter, aiming for double-digit EBITDA margin in FY'27.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Gland Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Investment of about INR 120 crores planned for a new cartridge line, expected to be installed by the end of this year.
- A ~60 million euro CAPEX over the next 2-3 years in Cenexi to increase capability and capacity, including:
- Adding a new pre-filled syringe line at Hérouville site for better realization per unit.
- Adding an additional vial line and lyophilization capacity in the Belgium site to boost high-value business.
- Focus on replacing inefficient lines and adding new capacities for lyophilized (Lyo) products to meet growing demand.
- Capacity expansion driven by supply constraints at two sites unable to cater to demand, particularly for Lyo products.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gland Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Cenexi's current order book is around Euro 100 million (Page 22).
- Cenexi has capacity constraints at two sites due to inefficient lines, leading to aggressive capacity expansion (Pages 20-21).
- The company is investing in new and more efficient lines to meet demand, particularly for lyophilized products (Page 21).
- For GLP (glucagon-like peptide) fill and finish, 40 million cartridges capacity is mostly booked; the second line will be operational by year-end to cater to additional partnerships (Pages 22-23).
2 more points management made on order book & pipeline
Gland Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹1.7K Cr, net profit ₹367 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gland Pharma's management said in earlier quarters
- Q3 FY26 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Biocon (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
- Natural Capsules Ltd (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Laurus Labs Ltd (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
- Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…
Frequently Asked Questions
What were Gland Pharma Ltd Q4 FY25 results?
FY'25 US volume growth: +9%, price decline: -5%; new launches contributed 6% to US revenue with a 72% gross margin. FY'26 overall growth guidance: mid-teens percentage (15%-17%), driven by US business growth, new launches, tech transfer projects, dry powder contracts, and biologics segment (~Rs 100 crores revenue expected in FY'26).
What is Gland Pharma Ltd share price analysis?
Gland Pharma Ltd currently shows a neutral. The stock trades at a P/E of 42.8 with a market cap of ₹48,998 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gland Pharma Ltd planning capital expenditure?
Investment of about INR 120 crores planned for a new cartridge line, expected to be installed by the end of this year.
Keep Gland Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.